Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Heart Failure Clinics

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.hfc.2017.12.006PMID 29525646PMCID PMC5849064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Publication : CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice

  2018cited by this paper
• Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

  2017cited by this paper
• Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease

  2017cited by this paper
• Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry

  2017cited by this paper
• Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes

  2017cited by this paper
• Myotonic dystrophy: approach to therapy.

  2017cited by this paper
• In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice

  2017cited by this paper
• Unexpected mutations after CRISPR–Cas9 editing in vivo

  2017cited by this paper
• Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

  2017cited by this paper
• Correction of a pathogenic gene mutation in human embryos

  2017cited by this paper
• Dilated Cardiomyopathy: Genetic Determinants and Mechanisms

  2017cited by this paper
• CASAAV: A CRISPR‐Based Platform for Rapid Dissection of Gene Function In Vivo

  2017cited by this paper
• Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT‐HF randomized phase 2 trial

  2017cited by this paper
• Human Germline Genome Editing.

  2017cited by this paper
• Human Embryo Editing: Opportunities and Importance of Transnational Cooperation.

  2017cited by this paper
• The chemical evolution of oligonucleotide therapies of clinical utility

  2017cited by this paper
• Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

  2017cited by this paper
• Targeted Genome Replacement via Homology-directed Repair in Non-dividing Cardiomyocytes

  2017cited by this paper
• Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.

  2017cited by this paper
• Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues

  2017cited by this paper
• Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome

  2016cited by this paper
• The ExAC browser: displaying reference data information from over 60 000 exomes

  2016cited by this paper
• In vivo gene editing in dystrophic mouse muscle and muscle stem cells

  2016cited by this paper
• Modulation of LMNA splicing as a strategy to treat prelamin A diseases.

  2016cited by this paper
• Antisense-Based Progerin Downregulation in HGPS-Like Patients’ Cells

  2016cited by this paper
• Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.

  2016cited by this paper
• Comparison of CRISPR/Cas9 and TALENs on editing an integrated EGFP gene in the genome of HEK293FT cells

  2016cited by this paper
• Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model

  2016cited by this paper
• CRISPR-Cas9 System as a Versatile Tool for Genome Engineering in Human Cells

  2016cited by this paper
• Dystrophin-Deficient Cardiomyopathy.

  2016cited by this paper
• Multidimensional chemical control of CRISPR-Cas9.

  2016cited by this paper
• Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

  2016cited by this paper
• Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

  2016cited by this paper
• The CRISPR Way to Think about Duchenne's.

  2016cited by this paper
• In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

  2016cited by this paper
• In vivo genome editing using Staphylococcus aureus Cas9

  2015cited by this paper
• Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies

  2015cited by this paper
• Arrhythmias in the muscular dystrophies.

  2015cited by this paper
• The Dystrophin Complex: Structure, Function, and Implications for Therapy.

  2015cited by this paper
• Analysis of protein-coding genetic variation in 60,706 humans

  2015cited by this paper
• Genome engineering using CRISPR-Cas9 system.

  2015cited by this paper
• Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity

  2015cited by this paper
• Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications

  2015cited by this paper
• Clinical applications of preimplantation genetic testing

  2015cited by this paper
• Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease

  2015cited by this paper
• Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping.

  2015cited by this paper
• Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy

  2015cited by this paper
• Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9.

  2014cited by this paper
• Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA

  2014cited by this paper
• Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies

  2014cited by this paper
• Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells

  2014cited by this paper
• Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases

  2014cited by this paper
• Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA

  2014cited by this paper
• Multiplex Genome Engineering Using CRISPR/Cas Systems

  2013cited by this paper
• Genome engineering using the CRISPR-Cas9 system

  2013cited by this paper
• ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

  2013cited by this paper
• Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis

  2013cited by this paper
• Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems

  2013cited by this paper
• Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice

  2013cited by this paper
• Arrhythmias in the muscular dystrophies.

  2012cited by this paper
• A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

  2012cited by this paper
• Efficient targeted gene disruption in Xenopus embryos using engineered transcription activator-like effector nucleases (TALENs)

  2012cited by this paper
• Arrhythmogenic right ventricular cardiomyopathy

  2011cited by this paper
• Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure

  2011cited by this paper
• Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting

  2011cited by this paper
• Targeting DNA Double-Strand Breaks with TAL Effector Nucleases

  2010cited by this paper
• Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations

  2009cited by this paper
• Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.

  2009cited by this paper
• Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy

  2009cited by this paper
• Highly efficient endogenous human gene correction using designed zinc-finger nucleases

  2005cited by this paper
• The Human Genome Project: Lessons from Large-Scale Biology

  2003cited by this paper
• This Work Is Licensed under a Creative Commons Attribution 4.0 International License the Treat-nmd Dmd Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations

  year unknowncited by this paper

• Gene editing therapy as a therapeutic approach for cardiovascular diseases in animal models: A scoping review

  2025cites this paper
• Emerging Therapeutic Strategies for Heart Failure: A Comprehensive Review of Novel Pharmacological and Molecular Targets

  2025cites this paper
• Dilated cardiomyopathy: from genes and molecules to potential treatments

  2025cites this paper
• Revolutionizing Cardiac Care: The Role of Gene Therapy in Treating Cardiomyopathy.

  2024cites this paper
• Genome Editing and Pathological Cardiac Hypertrophy.

  2023cites this paper
• Genome Editing and Heart Failure.

  2023cites this paper
• Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors

  2023cites this paper
• Cardiac Organoids: A 3D Technology for Modeling Heart Development and Disease

  2022cites this paper
• Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies

  2020cites this paper
• Information Retrieval for Genetic Mutations and Diseases

  2020cites this paper
• Genome Editing for the Understanding and Treatment of Cardiomyopathies

  2019cites this paper
• Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies.

  2019cites this paper
• On the Road from Gene to Therapy in Inherited Cardiomyopathies.

  2018cites this paper
• Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy

  2018cites this paper